Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today was recognized as the number one philanthropic funder of HIV-related programs for the second year in a row, in a new report released by Funders Concerned About AIDS (FCAA). FCAA's annual Philanthropic Support to Address HIV and AIDS report is widely regarded as the most comprehensive study of its kind, and analyzed data from more than 5,000 grants, disbursed by 187 funders and awarded to 2,800 grantee organizations.

Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS

AbbVie

Amgen

Here we pick three medical device stocks, AbbVie (ABBV), Amgen (AMGN) and Gilead Sciences (GILD), which have a solid five-year dividend growth history.

3 Biotech Stocks With Decent Dividend for a Steady Return

Gilead Sciences (GILD) concluded the recent trading session at $77.56, signifying a -0.31% move from its prior day's close.

Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know

Haleon PLC

Medtronic

Merck

Novartis

West Pharmaceutical Services

Zimmer Biomet Hlds

One of my favorite sectors will always be the healthcare sector. It is practically a basic need for all human beings and is always in constant development and growth.

7 Healthcare Stocks to invest in for a Healthy Future

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) presented new data today supporting Sunlenca® (lenacapavir) as an important treatment option for adults with multi-drug resistant (MDR) HIV who have extensive treatment history. These findings highlight the significance of lenacapavir, the first long-acting injectable HIV treatment medication administered twice-yearly, as a person-centric therapy option and its potential to help transform the future of coordinated HIV cl.

New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIV

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today new long-term real-world data from the BICSTaR study highlighting the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) as a treatment regimen for a broad range of people with HIV, including those with a prior treatment history or comorbidities. These findings were presented at the 19th European AIDS Conference (EACS 2023), takin.

Real-World Evidence Reinforces Biktarvy® as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of Comorbidities

AstraZeneca

AstraZeneca stock tumbled Wednesday after its experimental drug led to only a month's benefit over chemotherapy in lung cancer patients.

Why AstraZeneca's Disappointing Lung Cancer Update Also Tripped Gilead Stock

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced PURPOSE 5, the first Phase 2 clinical trial to evaluate an investigational long-acting HIV prevention option in Europe. The study will assess the persistence—defined as consistent and continuous use—of lenacapavir compared with emtricitabine/tenofovir disoproxil fumarate (F/TDF) in people who may benefit from pre-exposure prophylaxis (PrEP) and who are not currently taking PrEP. The study has an intention.

Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program

Archer-Daniels-Midland Company

Aflac

Allegion

Broadcom

Becton, Dickinson and Co.

Dover

Con Ed

Embecta Corp

Emerson Electric

W.W. Grainger

Johnson & Johnson

Kraft Heinz

Kontoor Brands Inc

LyondellBasell Industries

McDonald's

Microsoft

PepsiCo

Pfizer

Southern Company

T. Rowe Price Group

Trane Technologies plc

With the start of the final quarter of 2023, it's time to take a look back at my previous month of dividend income. Getting close to that $2,000 milestone in a month sure looks amazing. I know, those end of quarter months are always the big payers but it's still nice to see.

Dividend Income Update September 2023

Gilead Sciences Inc. GILD, +2.00% announced Tuesday a 12-year partnership Assembly Biosciences Inc. ASMB, +2.11% to develop antiviral therapies, with an initial focus in hepatitis B virus and hepatitis D virus. As part of the partnership, Gilead will pay Assembly $100 million, including $84.8 million upfront and a $15.2 million equity investment.

Gilead to pay Assembly Bio an initial $100 million as part of 12-year partnership to develop antiviral drugs

Assembly Biosciences

FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases.

Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases

FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present new data, including three oral presentations, at the European Society for Medical Oncology (ESMO) Congress 2023. New clinical data for Trodelvy® (sacituzumab govitecan-hziy) continue to support its use in metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) and demonstrate the expanding body of evidence fo.

Gilead and Kite Oncology Present Important New Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 19th European AIDS Conference (EACS) to be held in Warsaw, Poland from October 18-21, 2023. As a leader in HIV innovation, Gilead will provide an update on its signature initiatives, key collaborations and share new scientific data from its HIV research and development programs. The research that will be presented at EACS 2023, along with symposia led by Gilead, reflects.

Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023

Gilead Sciences is a California-based biopharmaceutical company with a $95 billion market cap, known for its treatments in HIV, hepatitis B, hepatitis C, and cancer. In Q2 2023, Gilead Sciences reported strong financial performance across various segments, though COVID-related sales fell sharply. In my opinion, GILD is dirt cheap despite its broad pipeline, solid profitability (EBITDA margin is quite solid), and low valuation multiples (~30% lower than the sector's medians).

Gilead Sciences Stock Is Cheap, With Broad Pipeline

Pfizer is on a roll of important approvals that will eventually fill the gap left by its coronavirus portfolio. Gilead Sciences has a deep lineup and pipeline that are especially concentrated around HIV and oncology.

2 Dirt Cheap High-Yield Dividend Stocks to Buy Right Now

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2023 financial results and guidance will be released on Tuesday, November 7, 2023 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's third quarter 2023 financial results and provide a business update. A live webcast will be available on the Investor Relations section of www.gilead.com and will be archived the.

Gilead Sciences to Release Third Quarter 2023 Financial Results on Tuesday, November 7, 2023

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $75.06, denoting a +0.43% change from the preceding trading day.

Gilead Sciences (GILD) Ascends But Remains Behind Market: Some Facts to Note

SAN FRANCISCO--(BUSINESS WIRE)--Roberts Law Firm US, PC and NastLaw LLC announce that a proposed settlement has been reached in a class action lawsuit (KPH Healthcare Services, Inc. v. Gilead Sciences, Inc., No. 20-cv-06961-EMC (N.D. Cal.) (coordinated with In re HIV Antitrust Litigation (formerly called Staley v. Gilead Sciences, Inc.), No. 3:19-cv-02573-EMC (N.D. Cal.)). The lawsuit alleges that Gilead engaged in a variety of alleged anticompetitive conduct in violation of federal antitrust l.

If You Purchased Brand or Generic Truvada or Atripla Directly From the Manufacturer, You May Receive a Payment From a Class Action Settlement; Gilead Agreed to Pay $246,750,000 Into a Settlement Fund, Announces Roberts Law Firm, PC and NastLaw LLC

SAN FRANCISCO--(BUSINESS WIRE)--‘Responsible Investors: Dump Gilead' Says AHF Ad.

'Responsible Investors: Dump Gilead' Says AHF Ad

Bristol-Myers

Duke Energy

Verizon

Public Storage

The risk to the market is mounting, and with it, volatility. The VIX is up nearly 50% in the last month and heading higher, which means the S&P 500 could be heading lower.

5 Low Beta, High-Yield Stocks for Your Low-Risk Income Portfolio

Gilead Sciences has outperformed the S&P 500 with a 19% total return since my last 'Buy' rating in August last year. Yet, the stock trades at a low PE ratio, especially after trading down over the past 10 months. GILD's strong cash flow, profitability, drug pipeline, and dividend yield make it a solid healthcare pick for income and potential gains.

Gilead Sciences: A Healthy Buy With Solid Dividend

Comcast

Ecolab

Estee Lauder

Intercontinental Exchange

Kenvue

Altria

Raytheon Technologies

U.S. Bancorp

Wells Fargo

Yum China Hlds

There's a bright side to the S&P 500's recent slide. Some stocks are set up for likely gains, at least according to a Morningstar strategist.

Morningstar Says Stocks Are 8% Undervalued — Likes These 13 Best

Agilent Technologies

Analog Devices

Autodesk

Amazon

American Express

Boeing

Bank of America

Biogen

Bank of New York Mellon

Blackrock Inc

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further analysis.

U.S. Wide-Moat Stocks On Sale - The October 2023 Heat Map

News for Gilead Sciences Stock (GILD)